Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas

Marc S. Hoffman, MD, provides an overview of recent updates in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.

Dr Marc S Hoffman reviews the currently available treatment options for relapsed/refractory follicular lymphoma.

A discussion on which patients with relapsed/refractory follicular lymphoma are good candidates for CAR T-cell therapy.

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.